Clinical Trials Logo

Metastatic Solid Tumors clinical trials

View clinical trials related to Metastatic Solid Tumors.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03993873 Active, not recruiting - Clinical trials for Advanced Solid Tumor

Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

SHIELD-1
Start date: September 21, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

A phase 1/2, first-in-human, open-label study of the safety, tolerability, PK, and efficacy of the novel MET/CSF1R/SRC inhibitor TPX-0022 in adult subjects with advanced or metastatic NSCLC, Gastric Cancer, or solid tumors harboring genetic alterations in MET. (SHIELD-I)

NCT ID: NCT03893955 Active, not recruiting - Cancer Clinical Trials

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

Start date: May 21, 2019
Phase: Phase 1
Study type: Interventional

A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in participants with selected solid tumors. This study consists of 2 main parts, a dose-escalation phase and a dose-expansion phase. The dose-expansion phase can begin once the recommended phase 2 dose/maximum tolerated dose (RP2D/MTD) is determined in the dose-escalation phase.

NCT ID: NCT01543763 Active, not recruiting - Clinical trials for Metastatic Solid Tumors

Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

Start date: June 25, 2012
Phase: Phase 1
Study type: Interventional

This is a open-label non-randomized, dose escalation and expansion Phase Ia/Ib study to determine the safety, tolerability and maximum tolerated dose (MTD) of pazopanib in combination with PCI-24781 in patients with advanced solid tumors.